Skip to content
ContentLora

    Tip: press / anywhere to search.

    Explainer

    Psychedelics law explained: federal bans, state programs, exemptions

    Under US federal law, psilocybin, LSD, MDMA, DMT, mescaline and peyote are Schedule I drugs, a category for substances with a high potential for abuse and no currently accepted medical use; ketamine is in Schedule III.[1][2][3] Oregon and Colorado have created state-licensed psilocybin programs, although psilocybin remains illegal under federal law, Federal regulations exempt religious use of peyote by the Native American Church, and in 2006 the Supreme Court ruled that the government had not shown a compelling interest in barring one church's sacramental use of a DMT-containing tea.[4][5][6][7][8] The FDA turned down an MDMA application in 2024, Compass Pathways still described its psilocybin product as investigational after completing its application in November 2026, and an April 2026 executive order pushed for faster research but did not change the drugs' legal status.[9][10][11][12]

    Editor reviewedStrict sourcingUpdated Explainer21 claims · 100% primaryDrugs, alcohol and addiction, Courts and the law, Mental health

    This explainer covers how US federal and state law treat psychedelic drugs, as of November 2026. It is general information, not legal or medical advice. Laws differ by state and change often; check the current law where you are, and talk to a clinician about any treatment. What the clinical trials show is covered in the psychedelic therapy analysis.

    SAMHSA’s National Helpline, 1-800-662-HELP (4357), is a free, confidential treatment referral and information service for people facing mental or substance use disorders, open 24 hours a day.[13]

    Federal law: Schedule I

    The Controlled Substances Act sorts drugs into schedules. A Schedule I drug has a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision.[2] Federal regulations list psilocybin, psilocyn, LSD, MDMA, DMT, mescaline, peyote and ibogaine in Schedule I.[1] Ketamine is in Schedule III.[3] Esketamine is an FDA-approved nasal spray for treatment-resistant depression and is given in a doctor’s office, clinic or hospital.[14]

    The US framework sits inside an international one. The 1971 UN Convention on Psychotropic Substances set up an international control system that brought a number of synthetic drugs under control according to their abuse potential and therapeutic value.[15] How a drug moves between schedules is shown in the cannabis rescheduling explainer.

    Religious exemptions

    Federal regulations exempt the non-drug use of peyote in bona fide religious ceremonies of the Native American Church from its Schedule I listing. Anyone who supplies peyote to the church must still register every year.[7]

    In Gonzales v. O Centro Espirita (2006), the Supreme Court held that the government had failed to show, at the preliminary injunction stage, a compelling interest under the Religious Freedom Restoration Act in barring a church’s sacramental use of hoasca, a tea containing the Schedule I hallucinogen DMT.[8] The government had argued that enforcement was needed partly to comply with the 1971 UN Convention; the district court held that the Convention does not apply to hoasca.[16]

    State psilocybin programs

    Oregon’s Measure 109, passed in November 2020 and now codified as ORS 475A, directs the Oregon Health Authority to license and regulate psilocybin products and services.[4] Services are open to people aged 21 or older, including non-residents, with no prescription or referral. A preparation session with a licensed facilitator must come first.[17] Products can be bought only at a licensed service center during an administration session and may not be taken away.[18]

    Colorado became the second state to legalise psilocybin mushrooms for personal use or use at healing centers when SB23-290 was signed in May 2023. Its Department of Revenue licenses businesses and its Department of Regulatory Agencies regulates facilitators.[5] State programs do not change federal law: the Oregon Health Authority notes that psilocybin is still a Schedule I substance under the Controlled Substances Act.[6]

    The medical approval route

    Drug developers have sought FDA approval for psychedelic medicines. In June 2024 an FDA advisory committee voted 9 to 2 that the data did not show MDMA was effective for PTSD.[19] On 9 August 2024 Lykos Therapeutics said the FDA had issued a complete response letter for its MDMA application and asked for another phase 3 study.[9] On 9 November 2026 Compass Pathways said it had completed its New Drug Application for COMP360, a synthetic psilocybin, in treatment-resistant depression.[10] Compass still described COMP360 as investigational, meaning not FDA-approved.[11]

    The 2026 executive order

    On 18 April 2026 President Trump signed Executive Order 14401, which encourages research on psychedelic drugs for mental health conditions.[20] It tells the Attorney General, consulting HHS, to review any Schedule I product that completes phase 3 trials for a serious mental health disorder so that rescheduling, if appropriate, can proceed.[21] The order did not change the legal status of psilocybin or other psychedelics.[12]

    More in Drugs & addiction

    Questions readers ask

    Are psychedelics legal in the US?

    Not under federal law. Psilocybin, psilocyn, LSD, MDMA, DMT, mescaline, peyote and ibogaine are listed in Schedule I. Oregon and Colorado license psilocybin services under state law, but the Oregon Health Authority notes psilocybin is still a Schedule I substance federally.[1][4][5][6]

    What does Schedule I mean?

    Under the Controlled Substances Act, a Schedule I drug has a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision.[2]

    How does Oregon's psilocybin program work?

    Oregon's 2020 Measure 109 directs the Oregon Health Authority to license psilocybin products and services. Services are open to people aged 21 or older with no prescription required, start with a preparation session with a licensed facilitator, and products can be bought and used only at a licensed service center during an administration session.[4][17][18]

    Is there a religious exemption for psychedelics?

    Federal regulations exempt the non-drug use of peyote in bona fide ceremonies of the Native American Church. In 2006 the Supreme Court held that the government had not shown a compelling interest, under the Religious Freedom Restoration Act, in barring one church's sacramental use of hoasca, a tea containing DMT.[7][8]

    Has the FDA approved MDMA or psilocybin?

    Not as of the latest developments covered here. In August 2024 the FDA issued a complete response letter for Lykos Therapeutics' MDMA application and asked for another phase 3 study. Compass Pathways completed a New Drug Application for its psilocybin product COMP360 on 9 November 2026, but described it as investigational.[9][10][11]

    What did the 2026 psychedelics executive order do?

    Executive Order 14401, signed on 18 April 2026, encourages psychedelic research and tells the Attorney General to review any Schedule I product that completes phase 3 trials for a serious mental health disorder so rescheduling can proceed if appropriate. It did not change the drugs' legal status.[20][21][12]

    Sources

    · 21 claims from 16 publishers

    Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.

    1. [1]

      Federal regulations list psilocybin, psilocyn, LSD, MDMA, DMT, mescaline, peyote and ibogaine in Schedule I. confirmedas of 2026-11-14

    2. [2]

      Under the US Controlled Substances Act, a Schedule I drug has a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision. confirmedas of 2026-11-14

    3. [3]

      Ketamine is listed in Schedule III of the federal drug schedules. confirmedas of 2026-11-14

    4. [4]

      Oregon's Measure 109, passed in November 2020 and codified as ORS 475A, directs the Oregon Health Authority to license and regulate psilocybin products and psilocybin services. confirmedas of 2026-11-07

    5. [5]

      Colorado's Department of Revenue says Colorado became the second state after Oregon to legalise psilocybin mushrooms for personal use or use by healing centers when SB23-290 was signed in May 2023, with the Department of Revenue licensing businesses and the Department of Regulatory Agencies regulating facilitators. confirmedas of 2026-11-07

    6. [6]

      The Oregon Health Authority describes psilocybin services as a health and wellness option in Oregon and notes that psilocybin remains a Schedule I substance under the federal Controlled Substances Act. confirmedas of 2026-11-07

    7. [7]

      Federal regulations exempt the non-drug use of peyote in bona fide religious ceremonies of the Native American Church from its Schedule I listing, though anyone supplying peyote to the church must register annually. confirmedas of 2026-11-14

    8. [8]

      In Gonzales v. O Centro Espirita (2006), the Supreme Court held that the government had failed to show, at the preliminary injunction stage, a compelling interest under the Religious Freedom Restoration Act in barring a church's sacramental use of hoasca, a tea containing the Schedule I hallucinogen DMT. confirmedas of 2006-02-21

    9. [9]

      On 9 August 2024 Lykos Therapeutics announced that the FDA had issued a complete response letter for its MDMA application and requested an additional phase 3 study, saying the issues echoed those raised at the advisory committee. confirmedas of 2024-08-09

    10. [10]

      On 9 November 2026 Compass Pathways announced that it had completed its New Drug Application to the FDA for COMP360 psilocybin in treatment-resistant depression. confirmedas of 2026-11-09

    11. [11]

      As of 9 November 2026, Compass described COMP360 as an investigational synthetic psilocybin formulation, meaning it was not FDA-approved. confirmedas of 2026-11-09

    12. [13]

      SAMHSA's National Helpline, 1-800-662-HELP (4357), is a free, confidential treatment referral and information service for people facing mental or substance use disorders, available 24 hours a day, 365 days a year. confirmedas of 2026-11-07

      • Resources (Adolescent Outcomes of Post-Operative Opioid Exposure Research) · Boston Children's Hospital · Secondary source (retrieved 2026-11-07)
      • Fentanyl · National Institute on Drug Abuse · Primary source · Help box, page footer (retrieved 2026-11-07)
      • Psychotherapies · National Institute of Mental Health (NIH) · Primary source · 2024-02-01 · Finding a therapist, helplines (retrieved 2026-10-11)
      • SAMHSA's National Helpline · Substance Abuse and Mental Health Services Administration · Primary source · Primary page; 403 to scripts on 2026-11-08, so not quoted here. Browser check. (retrieved 2026-11-08)
    13. [14]

      NIMH describes esketamine as an FDA-approved nasal spray for treatment-resistant depression, given in a doctor's office, clinic or hospital, that typically acts within a couple of hours. confirmedas of 2026-10-11

    14. [15]

      The 1971 UN Convention on Psychotropic Substances set up an international control system that brought a number of synthetic drugs under control according to their abuse potential and therapeutic value. confirmedas of 2026-11-14

    15. [16]

      In the O Centro case the government argued that enforcing the drug law was needed partly to comply with the 1971 UN Convention on Psychotropic Substances, while the district court held that the Convention does not apply to hoasca. confirmedas of 2006-02-21

    16. [17]

      Oregon's psilocybin services are open to people aged 21 or older, including non-residents, with no prescription or medical referral required, but a preparation session with a licensed facilitator must come first. confirmedas of 2026-11-07

    17. [18]

      Under Oregon law, psilocybin products can be bought only at a licensed service center during an administration session and may not be taken off-site. confirmedas of 2026-11-07

    18. [19]

      The advisory committee voted 9 to 2 that the available data did not show MDMA was effective in PTSD; many members said functional unblinding and unmanaged expectation and selection bias limited the efficacy analyses. confirmedas of 2024-06-04

    19. [20]

      On 18 April 2026 President Trump signed Executive Order 14401, "Accelerating Medical Treatments for Serious Mental Illness", which encourages research on psychedelic drugs for mental health conditions. confirmedas of 2026-04-22

    20. [21]

      The order also tells the Attorney General, consulting HHS, to begin and complete a review of any Schedule I product that has successfully completed phase 3 trials for a serious mental health disorder so that rescheduling, if appropriate, can proceed. confirmedas of 2026-04-22

    Revision history (1)
    1. Page created.

    Created Nov 14, 2026. Last reviewed by an editor on Nov 14, 2026. Next scheduled review: Feb 5, 2027.

    Cite this page

    "Psychedelics law explained: federal bans, state programs, exemptions." ContentLora, updated Nov 14, 2026. https://contentlora.com/explain/psychedelics-law-explained

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.